|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash Provided by (Used in) Operating Activities | |||||
| Net earnings (losses) | |||||
| Adjustments to reconcile net earnings to operating cash flows: | |||||
| Depreciation and amortization | |||||
| Deferred income tax provision (benefit) | |||||
| Unrecognized tax benefit | |||||
| Fair value adjustment for NJOY Transaction contingent payments, net of cash paid | |||||
| (Income) losses from investments in equity securities | |||||
| Gain on the sale of IQOS System commercialization rights | |||||
| Dividends from ABI | |||||
| Loss on Cronos-related financial instruments | |||||
| Loss on early extinguishment of debt | |||||
| Asset impairment and exit costs | |||||
| Impairment of goodwill | |||||
| Asset impairment and exit costs, net of cash paid | |||||
| Cash effects of changes: | |||||
| Receivables | |||||
| Inventories | |||||
| Accounts payable | |||||
| Income taxes | |||||
| Accrued liabilities and other current assets | |||||
| Accrued settlement charges | |||||
| Pension plan contributions | |||||
| Pension and postretirement, net | |||||
| Other, net | |||||
| Net cash provided by (used in) operating activities | |||||
| Cash Provided by (Used in) Investing Activities | |||||
| Capital expenditures | |||||
| Proceeds from the ABI Transaction | |||||
| Proceeds from the sale of IQOS System commercialization rights | |||||
| Proceeds from the Ste. Michelle Transaction, net of cash transferred | |||||
| Acquisition of NJOY, net of cash acquired | |||||
| Other, net | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash Provided by (Used in) Financing Activities | |||||
| Proceeds from short-term borrowings | |||||
| Repayment of short-term borrowings | |||||
| Long-term debt issued | |||||
| Long-term debt repaid | |||||
| Repurchases of common stock | |||||
| Dividends paid on common stock | |||||
| Premiums and fees related to early extinguishment of debt | |||||
| Other, net | |||||
| Net cash provided by (used in) financing activities | |||||
| Cash, cash equivalents and restricted cash: | |||||
| Increase (decrease) | |||||
| Balance at beginning of year | |||||
| Balance at end of year | |||||
| Supplemental cash flow information: | |||||
| Cash paid: Interest | |||||
| Deferred proceeds from the sale of IQOS System commercialization rights | |||||
| Cash Paid: Income taxes | |||||
| Cash and cash equivalents | |||||
| Restricted cash included in other current assets | |||||
| Restricted cash included in other assets | |||||
Loading...